obesity

Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
Pharmaceutical Business Review
obesity
peptide poly-agonists
Boehringer Ingelheim
Gubra
Flag link:
Even as obesity rates climb, new diabetes cases fall
Even as obesity rates climb, new diabetes cases fall
Stat
diabetes
obesity
Flag link:
FDA approves PureTech’s obesity device Plenity
FDA approves PureTech’s obesity device Plenity
Pharmaforum
FDA
PureTech Health
devices
obesity
Plenity
Flag link:
Obalon to lay off half its workforce in retail pivot
Obalon to lay off half its workforce in retail pivot
Mass Device
Obalon
layoffs
devices
obesity
Flag link:
Merck doubles down on NGM Bio pact but culls obesity drug
Merck doubles down on NGM Bio pact but culls obesity drug
Fierce Biotech
Merck
R&D
NGM Biopharmaceuticals
NP201
NASH
obesity
Flag link:
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market
BioSpace
obesity
Sanofi
Novo Nordisk
AstraZeneca
Flag link:
Obalon Scores Funding on the Heels of Obesity Market Shift
Obalon Scores Funding on the Heels of Obesity Market Shift
Medical Devices and Diagnostics Industry
Obalon
obesity
devices
Flag link:
LNC Therapeutics Acquires Exclusive License for Microbes Potentially Related to Obesity
LNC Therapeutics Acquires Exclusive License for Microbes Potentially Related to Obesity
CP Wire
LNC Therapeutics
microbiome
obesity
Flag link:
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs
Forbes
obesity
Belviq
Flag link:
Novo Nordisk adds to diabetes pipeline with Evotec deal
Novo Nordisk adds to diabetes pipeline with Evotec deal
Fierce Biotech
Novo Nordisk
Evotec
drug development
small molecule drugs
obesity
diabetes
Flag link:
Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?
Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?
Fierce Pharma
Eisai
obesity
Belviq
Flag link:
Omada Health launches new programs for obesity-related diseases
Omada Health launches new programs for obesity-related diseases
Healthcare Dive
Omada Health
digital therapeutics
hypertension
diabetes
obesity
Flag link:
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
Yahoo/Zacks.com
Novo Nordisk
R&D
Kallyope
diabetes
obesity
Flag link:
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Building up its rare obesity pipeline, Rhythm Pharma to raise $150M
Endpoints
Rhythm Pharmaceuticals
R&D
obesity
Flag link:
Gut Microbes Associated With Obesity May Contribute to Depression and Anxiety
Gut Microbes Associated With Obesity May Contribute to Depression and Anxiety
CP Wire
microbiome
obesity
anxiety
depression
Flag link:
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Novo Nordisk's semaglutide spurs major weight loss in phase 2 obesity study
Fierce Pharma
Novo Nordisk
obesity
semaglutide
Flag link:
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Endpoints
Novo Nordisk
obesity
semaglutide
Flag link:
Gelesis touts study of hydrogel obesity drug
Gelesis touts study of hydrogel obesity drug
Drug Delivery Business News
Gelesis
obesity
Gelesis100
Flag link:
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
Endpoints
Rhythm Pharmaceuticals
IPOs
obesity
rare disease
Flag link:
Novo focuses on new obesity therapy Semaglutide
Novo focuses on new obesity therapy Semaglutide
GoInPharma
Novo Nordisk
obesity
semaglutide
Flag link:

Pages